Nasal administration of metoclopramide from different dosage forms: In vitro, ex vivo, and in vivo evaluation

Drug Delivery

Volumn 16, Issue 3, 2009, Pages 167-175

  Tas, Cetin ^a   Ozkan, Cansel Kose ^a   Savaser, Ayhan ^a   Ozkan, Yalcin ^a   Tasdemir, Umut ^b   Altunay, Hikmet ^c  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b Lalahan Livestock Central Research Institute   (Turkey)

^c MEHMET AKIF ERSOY UNIVERSITY   (Turkey)

Author keywords

Cyclodextrin; Gel; Metoclopramide hydrochloride; Nasal drug delivery; Powder

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CARBOXYMETHYLCELLULOSE; METOCLOPRAMIDE; ANTIEMETIC AGENT; CELLULOSE; DRUG CARRIER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATTLE; CELL MEMBRANE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DIFFUSION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUTION; EX VIVO STUDY; GEL; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MICROSCOPY; MUCOADHESION; NONHUMAN; NOSE MUCOSA; POWDER; PRIORITY JOURNAL; ABSORPTION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFECT; HUMAN; INTRANASAL DRUG ADMINISTRATION; METABOLISM; PERMEABILITY;

ABSORPTION; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIEMETICS; BIOLOGICAL AVAILABILITY; CATTLE; CELLULOSE; DOSAGE FORMS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GELS; HUMANS; METOCLOPRAMIDE; NASAL MUCOSA; PERMEABILITY; POWDERS;

EID: 70349316282     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540902764172     Document Type: Article

References (41)

1. Martindale (2002). The complete drug reference. In: Sweetman SC, ed. (2002). Martindale: The complete drug reference, thirty- fifth edition, London: Pharmaceutical Press, 1235-1237
2. Gavini E, Rassu G, Sanna V, Cossu M, Giunchedi P. (2004). Mucoadhesive microspheres for nasal administration of an antiemetic drug, metoclopramide: in-vitro/ex-vivo studies. J Pharm Pharmacol, 57, 287-294
3. Chien YW. (1992). Nasal drug delivery systems. In: Swacbrick, J, ed. Novel drug delivery systems. New York: Marcel Dekker, 139-196
4. Zaki NM, Award GA, Mortada ND, Elhady SS. (2006). Rapid onset intranasal delivery of metoclopramide hydrochloride. Part II: safety of various absorption enhancers and pharmacokinetic evaluation. Int J Pharm, 327, 97-103.
5. Chavanpatil MD, Vavia PR. (2004). The influence of absorption enhancers on nasal absorption of acyclovir. Eur J Pharm Biopharm, 57, 483-487
6. Dondeti P, Zia H, Needham TE. (1996). Bioadhesive and formulation parameters affecting nasal absorption. Int J Pharm, 127, 115-133
7. Merkus FWHM, Verhoef JC, Marttin E, Romeijn SG, Van der Kuy PHM, Hermens WAJJ, Schipper NGM. (1999). Cyclodextrins in nasal drug delivery. Adv Drug Del Rev, 36, 41-57.
8. Ugwoke MI, Agu RU, Vanbilloen H, Baetens J, Augustijns P, Verbeke N, Mortelmans L, Verbruggen A, Kinget R, Bormans G. (2000). Scintigraphic evaluation in rabbits of nasal drug delivery systems based on carbopol 971p® and carboxymethylcellulose. J Contr Rel, 6, 207-214
9. Tas C, Ozkan Y, Savaşer A, Baykara T. (2003). In vitro release studies of chlorpheniramine maleate gels prepared by different cellulose derivatives. II Farmaco, 58, 605-611
10. Osth K, Paulsson M, Björk E, Edsman K. (2002). Evaluation of drug release from gels on pig nasal mucosa in a horizontal Ussing chamber. J Contr Rel, 83, 377-388 (Pubitemid 35223260)
11. Cheng Y-H, Watts P, Hinchcliffe M, Hotchkiss R, Nankervis R, Faraj NF, Smith A, Davis SS, Illum L. (2002). Development of a nasal nicotine formulation comprising an optimal pulsatile and sustained plasma nicotine profile for smoking cessation. J Contr Rel, 79, 243-254
12. Shargel L, Yu ABC. (1985). Applied biopharmaceutics and pharmacokinetics, 2nd ed. Norwalk: Appleton-Century-Crofts, 231-243
13. Tas C, Ozkan CK, Savaser A, Ozkan Y, Tasdemir U, Altunay H. (2006). Nasal absorption of metoclopramide from different carbopol® 981 based formulations: in vitro, ex vivo and in vivo evaluation. Eur J Pharm Biopharm, 64, 246-254
14. Escudero JJ, Ferrero C, Jimenez-Castellanos MR. (2008). Compaction properties, drug release kinetics and fronts movement studies from matrices combining mixtures of swellable and inert polymers: effect of HPMC of different viscosity grades. Int J Pharm, 351, 61-73.
15. Ma WD, Xu H, Wang C, Nie S-F, Pan W-S. (2008). Pluronic F127- g-poly(acrylic acid) copolymers as in situ gelling vehicle for opthalmic drug delivery system. Int J Pharm, 350, 247-256
16. Rajinikanth PS, Mishra B. (2008). Floating in situ gelling system for stomach site-spesific delivery of claritromycin to eradicate H.pylori. J Contr Rel, 125, 33-41.
17. Fang J-Y, Hwang T-L, Leu Y-L. (2003). Effect of enhancers and retarders on percutaneous absorption of flurbiprofen from hydrogels. Int J Pharm, 250, 313-325
18. D'Souza R, Mutalik S, Venkatesh M, Vidyasagar S, Udupa N. (2005). Nasal insulin gel as an alternate to parenteral insulin: formulation, preclinical, and clinical studies. AAPS Pharm Sci Tech, 6, 184-189
19. Charlton ST, Davis SS, Illum L. (2007). Evaluation of bioadhesive polymers as delivery systems for nose to brain delivery: in vitro characterisation studies. J Contr Rel, 118, 225-234
20. Mahato RI. (2004). Pharmaceutical delivery systems and dosage forms. New York: Castle Connoly, 37-64.
21. Zhang Y, Zhang Q, Sun Y, Sun J, Wang X, Chen M. (2005). Nasal recombinant hirudin-2 delivery: absorption and its mechanism in vivo and in vitro studies. Bio Pharm Bull, 28, 2263-2267 (Pubitemid 41757417)
22. Zaki NM, Awad GA, Mortada ND, Elhady SSA. (2007). Enhanced bioavailability of metoclopramide HCI by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Sci, 32, 296-307.
23. Behl CR, Pimplaskar HK, Sileno AP, deMeireles J, Romeo VD. (1998). Effects of physicochemical and other factors on systemic nasal drug delivery. Adv Drug Del Rev, 29, 89-116.
24. Aurora J. (2002). Development of nasal delivery systems. A Review. Drug Deliv Technol, 2(7), 70-73
25. Martin E, Romeijn SG, Verhoef JC, Merkus FWHM. (1997). Nasal absorption of dihydroergotamine from liquid and powder forrmulations in rabbits. J Pharm Sci, 86, 802-807
26. Asai K, Morishita M, Katsuta H, Hosoda S, Shinomiya K, Noro M, Nagai T, Takayama K. (2002). The effects of water-soluble cyclodextrins on the histological integrity of the rat nasal mucosa. Int J Pharm, 246, 25-35.
27. Arora P, Sharma S, Garg S. (2002). Permeability issues in nasal drug delivery. Drug Discov Today, 7, 967-975
28. Najafabadi AR, Moslemi P, Tajerzadeh H. (2004). Intranasal bioavailability of insulin from carbopol-based gel spray in rabbits. Drug Del, 11, 295-300.
29. Morimoto K, Tabata H, Morisaka K. (1987). Nasal absorption of nifedipine from gel preparations in rats. Chem Pharm Bull, 35, 3041-3044
30. Tuncel T, Otuk G, Kuscu I, Ates S. (1994). Nasal absorption of roxitromycin from gel preparations in rabbits. Eur J Pharm Biopharm, 40, 24-26
31. Yetkin G, Çelebi N, Agabeyoglu I, Gokcora N. (1999). The effect of dimethyl-β-cyclodextrin and sodium taurocholate on the nasal bioavailability of salmon calcitonin in rabbits. STP Pharm Sci, 9, 249-252
32. Ozsoy Y, Tuncel T, Can A, Akev N, Birteksoz S, Gerceker A. (2000). In vivo nasal studies on nasal preparations of ciprofloxacin hydrochloride. Pharmazie, 55, 607-609
33. Leitner VM, Guggi D, Bernkop-Schnurch A. (2004). Thiomers in noninvasive poypeptide delivery: in vitro and in vivo characterization of a polycarbophil-cysteine/glutathione gel formulation for human growth hormone. J Pharm Sci, 93, 1682-1691
34. Ishikawa F, Katsura M, Tamai I, Tsuji A. (2001). Improved nasal bioavailability of elcatonin by insoluble powder formulation. Int J Pharm, 224, 105-114
35. Leitner VM, Guggi D, Krauland AH, Bernkop-Schnürch A. (2004). Nasal delivery of human growth hormone: in vitro and in vivo evaluation of a thiomer/glutathione microparticulate delivery system. J Contr Rel, 100, 87-95.
36. Ugwoke MI, Exaud S, Mooter GVD, Verbeke N, Kinget R. (1999). Bioavailability of apomorphine following intranasal administration of mucoadhesive drug delivery systems in rabbits. Eur J Pharm Sci, 9, 213-219
37. Nakamura K, Maitani Y, Takayama K. (2002). The enhancing effect of nasal absorption of FITC-Dextran 4,400 by β-Sitosterol β-D-Glucoside in rabbits. J Contr Rel, 79, 147-155 (Pubitemid 34164168)
38. Gu F, Cui F, Gao Y. (2005). Preparation of prostaglandin E1-hydroxypropyl-β-cyclodextrin complex and its nasal delivery in rats. Int J Pharm, 290, 101-108
39. Irie T, Wakamatsu K, Arima H, Aritomi H, Uekama K. (1992). Enhancing effects of cyclodextrins on nasal absorption of insulin in rats. Int J Pharm, 84, 129-139
40. Sinswat P, Temgamnuay P. (2003). Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl- and dimethyl-β-cyclodextrins. Int J Pharm, 257, 15-22.
41. Yang T, Hussain A, Paulson J, Abbruscato TJ, Ahsan F. (2004). Cyclodextrins in nasal delivery of low-molecularweight heparins: in vivo and in vitro studies. Pharm Res, 21, 1127-1136